This archive report was first published on 10 September 2019.
Published on September 10, 2019, a recent shift in understanding has highlighted the importance of the human papillomavirus (HPV) vaccine in preventing cervical cancer and other related cancers.
For decades, lung cancer was a major concern, with smoking being the primary risk factor. However, with the rise of breast cancer and the impact of HIV, cervical cancer has become a leading cause of cancer deaths in women, closely followed by breast cancer and other cancers such as hepatitis B and liver cancer.
Cervical cancer is caused by the HPV virus, which is transmitted through sexual contact and can also cause other types of cancer, including genital warts and anal cancer. Men who have sex with men are at a higher risk, especially if they have HIV.
Fortunately, there is an effective vaccine available for cervical cancer and hepatitis B-causing liver cancer. The question remains: why vaccinate against a sexually transmitted virus if the person is already sexually active?
Recent studies have shown that even those who have had sex can benefit from the vaccine, and the Centers for Disease Control and Prevention (CDC) has expanded its recommendations to include individuals up to 45 years old, regardless of their sexual activity, as long as they have a clear pap smear screening.
Additionally, research suggests that sexually active women over 45 can be up to 45% protected by the vaccine. In light of this, I strongly support the use of the HPV vaccine in all women, regardless of their sexual activity, and also in boys. I personally received the Gardasil vaccine, and I believe it is a chance to prevent cancer, even if it is not a 100% guarantee.
